EA201692368A1 - Производные, полученные из гиалуроновой кислоты и карнозина - Google Patents

Производные, полученные из гиалуроновой кислоты и карнозина

Info

Publication number
EA201692368A1
EA201692368A1 EA201692368A EA201692368A EA201692368A1 EA 201692368 A1 EA201692368 A1 EA 201692368A1 EA 201692368 A EA201692368 A EA 201692368A EA 201692368 A EA201692368 A EA 201692368A EA 201692368 A1 EA201692368 A1 EA 201692368A1
Authority
EA
Eurasian Patent Office
Prior art keywords
carnosine
hyaluronic acid
derivatives obtained
derivatives
alanyl
Prior art date
Application number
EA201692368A
Other languages
English (en)
Other versions
EA032076B1 (ru
Inventor
Себастьяно Шюто
Валентина Греко
Энрико Риццарелли
Франческо Беллия
Валерия Ланца
Сузанна ВАККАРО
Лучиано Мессина
Original Assignee
Себастьяно Шюто
Консиглио Националь Делль Ричерче
Фидия Фармачеутичи С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Себастьяно Шюто, Консиглио Националь Делль Ричерче, Фидия Фармачеутичи С.П.А. filed Critical Себастьяно Шюто
Publication of EA201692368A1 publication Critical patent/EA201692368A1/ru
Publication of EA032076B1 publication Critical patent/EA032076B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/54—Proteins
    • A23V2250/55—Peptide, protein hydrolysate

Abstract

Настоящее изобретение относится к производному карнозина (β-аланил-L-гистидина), характеризующемуся формулой (1), полученному посредством функционализации гиалуроновой кислоты с помощью карнозина.
EA201692368A 2014-07-31 2015-07-30 Производные, полученные из гиалуроновой кислоты и карнозина EA032076B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20141395 2014-07-31
PCT/IB2015/055782 WO2016016847A1 (en) 2014-07-31 2015-07-30 Derivatives obtained from hyaluronic acid and carnosine

Publications (2)

Publication Number Publication Date
EA201692368A1 true EA201692368A1 (ru) 2017-04-28
EA032076B1 EA032076B1 (ru) 2019-04-30

Family

ID=51628371

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692368A EA032076B1 (ru) 2014-07-31 2015-07-30 Производные, полученные из гиалуроновой кислоты и карнозина

Country Status (10)

Country Link
US (1) US10364299B2 (ru)
EP (1) EP3174555B1 (ru)
KR (1) KR102394087B1 (ru)
CN (1) CN106573957B (ru)
CA (1) CA2951808C (ru)
EA (1) EA032076B1 (ru)
ES (1) ES2725874T3 (ru)
PL (1) PL3174555T3 (ru)
PT (1) PT3174555T (ru)
WO (1) WO2016016847A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600083975A1 (it) * 2016-08-09 2018-02-09 Consorzio Interuniversitario Naz Per La Scienza E Tecnologia Dei Materiali Acido ialuronico funzionalizzato
IT201700110784A1 (it) * 2017-10-03 2019-04-03 Fidia Farm Spa Composizioni farmaceutiche contenenti Acido Ialuronico e Carnosina e relativo uso
IT202000014017A1 (it) 2020-06-11 2021-12-11 Fidia Farm Spa Nuovi derivati ottenuti da acido ialuronico e carnosina
WO2023220754A1 (en) * 2022-05-13 2023-11-16 University Of Vermont And State Agricultural College Antioxidant derivative of hyaluronic acid
CN115215948B (zh) * 2022-06-02 2023-07-11 润辉生物技术（威海）有限公司 一种低分子的乙酰透明质酸脱羧肌肽衍生物、制备方法及应用
CN117050145B (zh) * 2023-10-11 2024-05-03 杭州湃肽生化科技有限公司 美容肽的透明质酸修饰物及其应用
CN117700583A (zh) * 2023-12-22 2024-03-15 珠海瑞玞生物工程有限公司 一种透明质酸基生物材料的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508728A (en) 1984-05-24 1985-04-02 Kineshiro Nagai Method of treating inflammatory diseases
DE4316293C2 (de) 1993-05-14 1996-05-09 Jobst Krauskopf Verwendung einer Kombination von Anserin/Carnosin und Hypotaurin/Taurin zur Bekämpfung entzündlicher Erkrankungen
IT1270905B (it) 1993-10-15 1997-05-13 Bruschettini Srl Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta
AUPQ515000A0 (en) 2000-01-19 2000-02-10 Grigg, Geoffrey Walter Treatment of uv induced immunosuppression
IT1318640B1 (it) * 2000-07-25 2003-08-27 Univ Catania Derivati di carnosina, procedimento per la loro preparazione ecomposizioni farmaceutiche che li contengono.
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
ITMI20060690A1 (it) * 2006-04-07 2007-10-08 Univ Catania Coniugato di trealpsio con carnlsina ad attivita'antiossidante stabile all'idrolisi enzimatica procedimenti per la sua preparazione e composizioni farmaceutiche cosmetiche e nutraceutiche che lo contengono
IT1407283B1 (it) * 2010-12-06 2014-04-04 Paoli Ambrosi De Nuovo composto di carnosina

Also Published As

Publication number Publication date
ES2725874T3 (es) 2019-09-30
CA2951808A1 (en) 2016-02-04
EP3174555A1 (en) 2017-06-07
EP3174555B1 (en) 2019-02-27
CN106573957B (zh) 2021-10-26
CN106573957A (zh) 2017-04-19
US20170246306A1 (en) 2017-08-31
PT3174555T (pt) 2019-05-28
US10364299B2 (en) 2019-07-30
EA032076B1 (ru) 2019-04-30
KR20170035924A (ko) 2017-03-31
KR102394087B1 (ko) 2022-05-03
WO2016016847A1 (en) 2016-02-04
CA2951808C (en) 2022-06-21
PL3174555T3 (pl) 2019-08-30

Similar Documents

Publication Publication Date Title
EA201692193A1 (ru) Способы получения ингибитора jak1 и его новых форм
EA201692368A1 (ru) Производные, полученные из гиалуроновой кислоты и карнозина
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
AU2014375265A1 (en) Novel pyrazolyl-heteroarylamides as pesticides
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201692219A1 (ru) Способы получения противовирусных соединений
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201792021A1 (ru) Ингибитор jak
EA201692548A1 (ru) Минеральные аминокислотные комплексы активных веществ
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
EA201591349A1 (ru) Способ получения вортиоксетина
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
BR112016027455A2 (pt) moduladores ppar